Moderna Reports Successful Trial of Flu Vaccine, Plans More Treatments Ahead
September 13, 2023
74 Views
1 Min Read
Moderna (MRNA) was the best-performing stock in the S&P 500 as the vaccine maker reported its experimental flu shot met its primary endpoint in a Phase 3 trial.